Irinotecan Hcl-Trihydraat Accord (Irinotecan Hydrochloride Trihydrate)

The drug is a pro‑drug that is converted inside cancer cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, preventing DNA religation during replication, which leads to DNA strand breaks, inhibition of cell division, and tumor cell death.

The dosing regimen is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, liver function, prior treatment history, and overall clinical condition. No fixed dose can be provided without a medical assessment.

Safety data for Irinotecan in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class and is often used after or in combination with fluoropyrimidines and oxaliplatin. Compared with agents like oxaliplatin, Irinotecan has a distinct toxicity profile, featuring more pronounced diarrhea and neutropenia, but offers an effective alternative for patients who progress on other regimens.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

Irinotecan is given as an intravenous infusion, usually over 30 to 90 minutes depending on the protocol. The infusion is performed by qualified healthcare personnel in a clinical setting, with appropriate monitoring for infusion‑related reactions and vital signs.

The most critical adverse events include severe neutropenia (which can lead to infection), life‑threatening diarrhea or colitis, hepatic toxicity, and rare allergic reactions. Prompt recognition and supportive care are essential to mitigate these risks.

Patients with known hypersensitivity to Irinotecan or any of its excipients, those with severe hepatic impairment, and individuals with uncontrolled infections or active severe bone‑marrow suppression should not be treated with Irinotecan. Clinical judgment is required for all other cases.